Last reviewed · How we verify
NCT07441343
Effects of Polyphenol Supplementation and Exercise on Physical Performance in Older Adults: A Randomized Controlled Pilot Feasibility Trial
NA trial testing Polyphenol Rich-Extract in Sarcopenia in 40 participants. Currently enrolling.
1 June 2026
Quick facts
| Lead sponsor | Dr. Chris McGlory, PhD |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | basic science |
| Enrollment | 40 |
| Start date | 1 September 2025 |
| Primary completion | 1 June 2026 |
| Estimated completion | 1 June 2026 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Polyphenol Rich-Extract
- Maltodextrin (Placebo) — full drug profile →
- Resistance Band-Based & Aerobic Stationary Cycling Exercise
Conditions studied
- Sarcopenia — all drugs for Sarcopenia →
- Aging — all drugs for Aging →
- Frailty — all drugs for Frailty →
Sponsor
Dr. Chris McGlory, PhD
Who can join
60 and older, any sex, with Sarcopenia or Aging. Healthy volunteers can join.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Feasibility of Retention
Time frame: 18 months, 12 weeks
Retention is expressed as the percentage of participants who completed baseline testing, the 12-week intervention, and post-testing visits, relative to those who completed baseline testing but did not finish. Success is defined as at least 75% (≥30 of 40) completing the study while maintaining adherence above 75% for both exercise sessions and supplementation. -
Feasibility of Recruitment
Time frame: 18 months
Number of participants recruited. Success is defined as recruitment of 40 participants across 18 months. -
Leg Extensor Strength
Time frame: -1 week, 6 weeks, 12 weeks
Change in leg-extensor peak torque measured by isometric dynamometry in Newton meters (Nm).
Sponsor's own description
After approximately age 40 years, individuals experience a natural loss of muscle mass, strength, and physical function that is linked to higher risks of falls, disability, loss of independence, and mortality. These losses can also be a precursor to the development of frailty, which includes factors beyond impaired physical function such as cognitive impairment, psychological disorder, increased likelihood of hospitalization, need of long term-care, and mortality. Structured exercise-encompassing both resistance and aerobic training-is widely recognized as an effective lifestyle intervention for improving muscle health, cardiovascular capacity, and overall physical function in older adults. However, aging is accompanied by chronically elevated systemic inflammation, and although exercise remains highly beneficial, older adults exhibit a heightened inflammatory response to training and a diminished capacity for post-exercise recovery. Polyphenols, a group of naturally occurring bioactive compounds, have been shown to possess both anti-inflammatory and antioxidant benefits, positively impacting recovery and health. Polyphenol supplementation, particularly when paired with structured exercise, may elicit synergistic improvements in physical performance through combined effects on oxidative stress, inflammation, and muscle recovery, making polyphenols a compelling adjunct strategy for mitigating sarcopenia. In pursuit of refining strategies that support healthy aging and preserve functional capacity in older adults, this study aimed to determine the feasibility of implementing a 12-week resistance and aerobic exercise program combined with dietary supplementation in older adults. Participants will either consume a polyphenol blend or a placebo control of maltodextrin daily whilst undergoing 12 weeks of supervised resistance and aerobic exercise. Additionally, this study will test the hypothesis that polyphenol supplementation will augment the exercise-induced improvements in physical function and muscle health. Further, exploratory analyses of skeletal muscle biopsy and venous plasma samples will aid in elucidating the potential geroprotective effects of polyphenols at both cellular and molecular levels.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07441343
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Sarcopenia
Currently open trials in the same condition.
- NCT07500376 — Multimodal Nutritional and Sarcopenia Assessment for Risk Stratification in Lung Cancer Surgery · recruiting
- NCT07456956 — HIIT vs MCIT for Stroke-Related Sarcopenia in Ischemic Stroke · NA · recruiting
- NCT07398495 — Multimodal Training Effects in Middle-Aged and Older Adults With Diabetic Sarcopenia · NA · recruiting
- NCT07494916 — Effects of Functional Task Training on Muscle Health and Function in Older Adults With Sarcopenia · NA · active not recruiting
- NCT07426159 — AI-Guided Sarcopenia Risk Assessment and Detection · NA · active not recruiting
Other Dr. Chris McGlory, PhD trials
Trials by the same sponsor.
- NCT06233825 — Nutritional Intervention to Enhance Recovery After Arthroscopic Knee Surgery in Adults · NA · completed
- NCT06137066 — The Effect of Green Coffee Extract on Blood Glucose Homeostasis in Healthy Adults · NA · completed
- NCT05971147 — Time Course Change in Skeletal Muscle and Blood Phospholipid Composition With Omega-3 Fatty Acid Supplementation · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07441343 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dr. Chris McGlory, PhD
- Last refreshed: 24 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07441343.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing